November 20, 2019 / 5:47 PM / 18 days ago

U.S. FDA approves Alnylam's drug for rare genetic disorder

Nov 20 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved Alnylam Pharmaceuticals Inc’s gene silencing drug as a treatment for patients with a rare inherited disorder.

The drug was approved to treat acute hepatic porphyria, a genetic disorder that can cause seizures and back pains. (bit.ly/37oqz9Z)

The drug, known as Givlaari, uses a mechanism known as RNA interference to target and “silence” specific genetic material, blocking the production of the deadly protein that causes the disease.

Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below